Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

Marian J. Stevens-Kroef, Daniel Olde Weghuis, Najat ElIdrissi-Zaynoun, Bert van der Reijden, Eline M.P. Cremers, Canan Alhan, Theresia M. Westers, Heleen A. Visser-Wisselaar, Dana A. Chitu, Sonia M. Cunha, Edo Vellenga, Saskia K. Klein, Pierre Wijermans, Georgine E. de Greef, M. Ron Schaafsma, Petra Muus, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Joop H. Jansen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Karyotyping is considered as the gold standard in the genetic subclassification of myelodysplastic syndrome (MDS). Oligo/SNP-based genomic array profiling is a high-resolution tool that also enables genome wide analysis. We compared karyotyping with oligo/SNP-based array profiling in 104 MDS patients from the HOVON-89 study. Oligo/SNP-array identified all cytogenetically defined genomic lesions, except for subclones in two cases and balanced translocations in three cases. Conversely, oligo/SNP-based genomic array profiling had a higher success rate, showing 55 abnormal cases, while an abnormal karyotype was found in only 35 patients. In nine patients whose karyotyping was unsuccessful because of insufficient metaphases or failure, oligo/SNP-based array analysis was successful. Based on cytogenetic visible abnormalities as identified by oligo/SNP-based genomic array prognostic scores based on IPSS/-R were assigned. These prognostic scores were identical to the IPSS/-R scores as obtained with karyotyping in 95%-96% of the patients. In addition to the detection of cytogenetically defined lesions, oligo/SNP-based genomic profiling identified focal copy number abnormalities or regions of copy neutral loss of heterozygosity that were out of the scope of karyotyping and fluorescence in situ hybridization. Of interest, in 26 patients we demonstrated such cytogenetic invisible abnormalities. These abnormalities often involved regions that are recurrently affected in hematological malignancies, and may therefore be of clinical relevance. Our findings indicate that oligo/SNP-based genomic array can be used to identify the vast majority of recurrent cytogenetic abnormalities in MDS. Furthermore, oligo/SNP-based array profiling yields additional genetic abnormalities that may be of clinical importance.

Original languageEnglish
Pages (from-to)524-534
Number of pages11
JournalGenes Chromosomes and Cancer
Volume56
Issue number7
DOIs
Publication statusPublished - 1 Jul 2017

Cite this

Stevens-Kroef, M. J., Olde Weghuis, D., ElIdrissi-Zaynoun, N., van der Reijden, B., Cremers, E. M. P., Alhan, C., ... Jansen, J. H. (2017). Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. Genes Chromosomes and Cancer, 56(7), 524-534. https://doi.org/10.1002/gcc.22455
Stevens-Kroef, Marian J. ; Olde Weghuis, Daniel ; ElIdrissi-Zaynoun, Najat ; van der Reijden, Bert ; Cremers, Eline M.P. ; Alhan, Canan ; Westers, Theresia M. ; Visser-Wisselaar, Heleen A. ; Chitu, Dana A. ; Cunha, Sonia M. ; Vellenga, Edo ; Klein, Saskia K. ; Wijermans, Pierre ; de Greef, Georgine E. ; Schaafsma, M. Ron ; Muus, Petra ; Ossenkoppele, Gert J. ; van de Loosdrecht, Arjan A. ; Jansen, Joop H. / Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. In: Genes Chromosomes and Cancer. 2017 ; Vol. 56, No. 7. pp. 524-534.
@article{09d423e39f0d4192b83af3ebb442ee5c,
title = "Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial",
abstract = "Karyotyping is considered as the gold standard in the genetic subclassification of myelodysplastic syndrome (MDS). Oligo/SNP-based genomic array profiling is a high-resolution tool that also enables genome wide analysis. We compared karyotyping with oligo/SNP-based array profiling in 104 MDS patients from the HOVON-89 study. Oligo/SNP-array identified all cytogenetically defined genomic lesions, except for subclones in two cases and balanced translocations in three cases. Conversely, oligo/SNP-based genomic array profiling had a higher success rate, showing 55 abnormal cases, while an abnormal karyotype was found in only 35 patients. In nine patients whose karyotyping was unsuccessful because of insufficient metaphases or failure, oligo/SNP-based array analysis was successful. Based on cytogenetic visible abnormalities as identified by oligo/SNP-based genomic array prognostic scores based on IPSS/-R were assigned. These prognostic scores were identical to the IPSS/-R scores as obtained with karyotyping in 95{\%}-96{\%} of the patients. In addition to the detection of cytogenetically defined lesions, oligo/SNP-based genomic profiling identified focal copy number abnormalities or regions of copy neutral loss of heterozygosity that were out of the scope of karyotyping and fluorescence in situ hybridization. Of interest, in 26 patients we demonstrated such cytogenetic invisible abnormalities. These abnormalities often involved regions that are recurrently affected in hematological malignancies, and may therefore be of clinical relevance. Our findings indicate that oligo/SNP-based genomic array can be used to identify the vast majority of recurrent cytogenetic abnormalities in MDS. Furthermore, oligo/SNP-based array profiling yields additional genetic abnormalities that may be of clinical importance.",
author = "Stevens-Kroef, {Marian J.} and {Olde Weghuis}, Daniel and Najat ElIdrissi-Zaynoun and {van der Reijden}, Bert and Cremers, {Eline M.P.} and Canan Alhan and Westers, {Theresia M.} and Visser-Wisselaar, {Heleen A.} and Chitu, {Dana A.} and Cunha, {Sonia M.} and Edo Vellenga and Klein, {Saskia K.} and Pierre Wijermans and {de Greef}, {Georgine E.} and Schaafsma, {M. Ron} and Petra Muus and Ossenkoppele, {Gert J.} and {van de Loosdrecht}, {Arjan A.} and Jansen, {Joop H.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1002/gcc.22455",
language = "English",
volume = "56",
pages = "524--534",
journal = "Genes, Chromosomes and Cancer",
issn = "1045-2257",
number = "7",

}

Stevens-Kroef, MJ, Olde Weghuis, D, ElIdrissi-Zaynoun, N, van der Reijden, B, Cremers, EMP, Alhan, C, Westers, TM, Visser-Wisselaar, HA, Chitu, DA, Cunha, SM, Vellenga, E, Klein, SK, Wijermans, P, de Greef, GE, Schaafsma, MR, Muus, P, Ossenkoppele, GJ, van de Loosdrecht, AA & Jansen, JH 2017, 'Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial' Genes Chromosomes and Cancer, vol. 56, no. 7, pp. 524-534. https://doi.org/10.1002/gcc.22455

Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. / Stevens-Kroef, Marian J.; Olde Weghuis, Daniel; ElIdrissi-Zaynoun, Najat; van der Reijden, Bert; Cremers, Eline M.P.; Alhan, Canan; Westers, Theresia M.; Visser-Wisselaar, Heleen A.; Chitu, Dana A.; Cunha, Sonia M.; Vellenga, Edo; Klein, Saskia K.; Wijermans, Pierre; de Greef, Georgine E.; Schaafsma, M. Ron; Muus, Petra; Ossenkoppele, Gert J.; van de Loosdrecht, Arjan A.; Jansen, Joop H.

In: Genes Chromosomes and Cancer, Vol. 56, No. 7, 01.07.2017, p. 524-534.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial

AU - Stevens-Kroef, Marian J.

AU - Olde Weghuis, Daniel

AU - ElIdrissi-Zaynoun, Najat

AU - van der Reijden, Bert

AU - Cremers, Eline M.P.

AU - Alhan, Canan

AU - Westers, Theresia M.

AU - Visser-Wisselaar, Heleen A.

AU - Chitu, Dana A.

AU - Cunha, Sonia M.

AU - Vellenga, Edo

AU - Klein, Saskia K.

AU - Wijermans, Pierre

AU - de Greef, Georgine E.

AU - Schaafsma, M. Ron

AU - Muus, Petra

AU - Ossenkoppele, Gert J.

AU - van de Loosdrecht, Arjan A.

AU - Jansen, Joop H.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Karyotyping is considered as the gold standard in the genetic subclassification of myelodysplastic syndrome (MDS). Oligo/SNP-based genomic array profiling is a high-resolution tool that also enables genome wide analysis. We compared karyotyping with oligo/SNP-based array profiling in 104 MDS patients from the HOVON-89 study. Oligo/SNP-array identified all cytogenetically defined genomic lesions, except for subclones in two cases and balanced translocations in three cases. Conversely, oligo/SNP-based genomic array profiling had a higher success rate, showing 55 abnormal cases, while an abnormal karyotype was found in only 35 patients. In nine patients whose karyotyping was unsuccessful because of insufficient metaphases or failure, oligo/SNP-based array analysis was successful. Based on cytogenetic visible abnormalities as identified by oligo/SNP-based genomic array prognostic scores based on IPSS/-R were assigned. These prognostic scores were identical to the IPSS/-R scores as obtained with karyotyping in 95%-96% of the patients. In addition to the detection of cytogenetically defined lesions, oligo/SNP-based genomic profiling identified focal copy number abnormalities or regions of copy neutral loss of heterozygosity that were out of the scope of karyotyping and fluorescence in situ hybridization. Of interest, in 26 patients we demonstrated such cytogenetic invisible abnormalities. These abnormalities often involved regions that are recurrently affected in hematological malignancies, and may therefore be of clinical relevance. Our findings indicate that oligo/SNP-based genomic array can be used to identify the vast majority of recurrent cytogenetic abnormalities in MDS. Furthermore, oligo/SNP-based array profiling yields additional genetic abnormalities that may be of clinical importance.

AB - Karyotyping is considered as the gold standard in the genetic subclassification of myelodysplastic syndrome (MDS). Oligo/SNP-based genomic array profiling is a high-resolution tool that also enables genome wide analysis. We compared karyotyping with oligo/SNP-based array profiling in 104 MDS patients from the HOVON-89 study. Oligo/SNP-array identified all cytogenetically defined genomic lesions, except for subclones in two cases and balanced translocations in three cases. Conversely, oligo/SNP-based genomic array profiling had a higher success rate, showing 55 abnormal cases, while an abnormal karyotype was found in only 35 patients. In nine patients whose karyotyping was unsuccessful because of insufficient metaphases or failure, oligo/SNP-based array analysis was successful. Based on cytogenetic visible abnormalities as identified by oligo/SNP-based genomic array prognostic scores based on IPSS/-R were assigned. These prognostic scores were identical to the IPSS/-R scores as obtained with karyotyping in 95%-96% of the patients. In addition to the detection of cytogenetically defined lesions, oligo/SNP-based genomic profiling identified focal copy number abnormalities or regions of copy neutral loss of heterozygosity that were out of the scope of karyotyping and fluorescence in situ hybridization. Of interest, in 26 patients we demonstrated such cytogenetic invisible abnormalities. These abnormalities often involved regions that are recurrently affected in hematological malignancies, and may therefore be of clinical relevance. Our findings indicate that oligo/SNP-based genomic array can be used to identify the vast majority of recurrent cytogenetic abnormalities in MDS. Furthermore, oligo/SNP-based array profiling yields additional genetic abnormalities that may be of clinical importance.

UR - http://www.scopus.com/inward/record.url?scp=85017401325&partnerID=8YFLogxK

U2 - 10.1002/gcc.22455

DO - 10.1002/gcc.22455

M3 - Article

VL - 56

SP - 524

EP - 534

JO - Genes, Chromosomes and Cancer

JF - Genes, Chromosomes and Cancer

SN - 1045-2257

IS - 7

ER -

Stevens-Kroef MJ, Olde Weghuis D, ElIdrissi-Zaynoun N, van der Reijden B, Cremers EMP, Alhan C et al. Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial. Genes Chromosomes and Cancer. 2017 Jul 1;56(7):524-534. https://doi.org/10.1002/gcc.22455